{"title":"Correction to “Efficacy of Trametinib in a Metastatic Urothelial Carcinoma Patient With a BRAF Mutation: A Case Report”","authors":"","doi":"10.1002/iju5.70047","DOIUrl":null,"url":null,"abstract":"<p>H. Karasawa, Y. Yasumizu, T. Kosaka, Shimoi, and M. Oya, “Efficacy of trametinib in a metastatic urothelial carcinoma patientwith a BRAF mutation,” <i>IJU Case Reports</i> 7, no. 5 (2024): 375-378, https://doi.org/10.1002/iju5.12759.</p><p>In the ‘Case presentation’ section, the first two sentences in the second paragraph read as follows: To provide further treatment for this patient, we conducted cancer multigene panel testing (FoundationOne®). We examined 324 cancer-related genes and identified the BRAF G469A mutations (Fig. 2).</p><p>The authors would like to clarify that the cancer panel test was performed at the referring hospital and not at the authors’ hospital. The correct text should be: To provide further treatment for this patient, cancer multigene panel testing (FoundationOne®) was conducted. Analysis of 324 cancer-related genes revealed the BRAF G469A mutation (Fig. 2).</p>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70047","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
H. Karasawa, Y. Yasumizu, T. Kosaka, Shimoi, and M. Oya, “Efficacy of trametinib in a metastatic urothelial carcinoma patientwith a BRAF mutation,” IJU Case Reports 7, no. 5 (2024): 375-378, https://doi.org/10.1002/iju5.12759.
In the ‘Case presentation’ section, the first two sentences in the second paragraph read as follows: To provide further treatment for this patient, we conducted cancer multigene panel testing (FoundationOne®). We examined 324 cancer-related genes and identified the BRAF G469A mutations (Fig. 2).
The authors would like to clarify that the cancer panel test was performed at the referring hospital and not at the authors’ hospital. The correct text should be: To provide further treatment for this patient, cancer multigene panel testing (FoundationOne®) was conducted. Analysis of 324 cancer-related genes revealed the BRAF G469A mutation (Fig. 2).
H. Karasawa， Y. Yasumizu， T. Kosaka， Shimoi和M. Oya，“曲美替尼治疗BRAF突变转移性尿路上皮癌的疗效”，《IJU病例报告》第7期。5 (2024): 375-378, https://doi.org/10.1002/iju5.12759.In“病例报告”部分，第二段的前两句如下：为了为该患者提供进一步的治疗，我们进行了癌症多基因面板检测（FoundationOne®）。我们检测了324个癌症相关基因，并确定了BRAF G469A突变（图2）。作者想澄清的是，癌症小组测试是在转诊医院进行的，而不是在作者所在的医院。正确的文字应该是：为了给该患者提供进一步的治疗，我们进行了癌症多基因面板检测（FoundationOne®）。对324个癌症相关基因的分析显示BRAF G469A突变（图2）。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
